British Thoracic Society Clinical Statement on chronic cough in adults
(2023)
Journal Article
Parker, S. M., Smith, J. A., Birring, S. S., Chamberlain-Mitchell, S., Gruffydd-Jones, K., Haines, J., Hennessey, S., McGarvey, L. P., Marsden, P., Martin, M. J., Morice, A., O'Hara, J., & Thomas, M. (2023). British Thoracic Society Clinical Statement on chronic cough in adults. Thorax, 78(Supp.6), s3-s19. https://doi.org/10.1136/thorax-2023-220592
Professor Alyn Morice's Outputs (10)
Consensus goals and standards for specialist cough clinics: the NEUROCOUGH international Delphi study (2023)
Journal Article
Song, W. J., Dupont, L., Birring, S. S., Chung, K. F., Dąbrowska, M., Dicpinigaitis, P., Ribas, C. D., Fontana, G., Gibson, P. G., Guilleminault, L., Hull, J. H., Idzko, M., Kardos, P., Kim, H. J., Lai, K., Lavorini, F., Millqvist, E., Morice, A. H., Niimi, A., Parker, S. M., …McGarvey, L. P. (2023). Consensus goals and standards for specialist cough clinics: the NEUROCOUGH international Delphi study. ERJ Open Research, 9(6), Article 00618-2023. https://doi.org/10.1183/23120541.00618-2023Background Current guidelines on the management of chronic cough do not provide recommendations for the operation of specialist cough clinics. The objective of the present study was to develop expert consensus on goals and standard procedures for spe... Read More about Consensus goals and standards for specialist cough clinics: the NEUROCOUGH international Delphi study.
New Insights Into Refractory Chronic Cough and Unexplained Chronic Cough: A 6-Year Ambispective Cohort Study (2023)
Journal Article
Zhang, M., Morice, A. H., Si, F., Zhang, L., Chen, Q., Wang, S., Zhu, Y., Xu, X., Yu, L., & Qiu, Z. (2023). New Insights Into Refractory Chronic Cough and Unexplained Chronic Cough: A 6-Year Ambispective Cohort Study. Allergy Asthma and Immunology Research, 15(6), 795-811. https://doi.org/10.4168/aair.2023.15.6.795Purpose: Only limited studies have depicted the unique features and management of refractory chronic cough (RCC) and unexplained chronic cough (UCC). These led to the initiation of this study, which reported the demographic characteristics, manifesta... Read More about New Insights Into Refractory Chronic Cough and Unexplained Chronic Cough: A 6-Year Ambispective Cohort Study.
Efficacy and safety of pharmacotherapy for refractory or unexplained chronic cough: a systematic review and network meta-analysis (2023)
Journal Article
Zheng, Z., Huang, J., Xiang, Z., Wu, T., Lan, X., Xie, S., Lin, Z., Tang, K., Morice, A., Li, S., Song, W. J., & Chen, R. (2023). Efficacy and safety of pharmacotherapy for refractory or unexplained chronic cough: a systematic review and network meta-analysis. EClinicalMedicine, 62, Article 102100. https://doi.org/10.1016/j.eclinm.2023.102100Background: Refractory chronic cough (RCC) has a significant impact on patient's health-related quality of life and represents a challenge in clinical management. However, the optimal treatment for RCC remains controversial. This study aimed to inves... Read More about Efficacy and safety of pharmacotherapy for refractory or unexplained chronic cough: a systematic review and network meta-analysis.
Reply to Weinberger (2023)
Journal Article
Birring, S. S., Morice, A. H., Dicpinigaitis, P. V., McGarvey, L. P., Pavord, I. D., Green, S. A., Philip, G., & Smith, J. A. (2023). Reply to Weinberger. American Journal of Respiratory and Critical Care Medicine, 207(12), 1650-1651. https://doi.org/10.1164/rccm.202304-0709LE
Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study (2023)
Journal Article
Dicpinigaitis, P. V., Morice, A. H., Smith, J. A., Sher, M. R., Vaezi, M., Guilleminault, L., Niimi, A., Gude, K., Krahn, U., Saarinen, R., Pires, P. V., Wosnitza, M., & McGarvey, L. (2023). Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study. Lung, 201, Article 255-266. https://doi.org/10.1007/s00408-023-00621-xIntroduction: The PAGANINI study evaluated the efficacy and safety of the selective P2X3 antagonist eliapixant in patients with refractory chronic cough (RCC). Methods: PAGANINI was a randomized, double-blind, parallel-group, placebo-controlled, mult... Read More about Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study.
Improving asthma care through implementation of the SENTINEL programme: findings from the pilot site (2023)
Journal Article
Crooks, M. G., Crowther, L., Cummings, H., Cohen, J., Huang, C., Pitel, L., Pearson, M., Morice, A., Turgoose, J., Faruqi, S., Watt, M., Morris, T., & Xu, Y. (2023). Improving asthma care through implementation of the SENTINEL programme: findings from the pilot site. ERJ Open Research, 9(3), Article 00685-2022. https://doi.org/10.1183/23120541.00685-2022Aim: Short-acting β2-agonist (SABA) overuse adversely impacts asthma-related outcomes and the environment. The SABA rEductioN Through ImplemeNting Hull asthma guidELines (SENTINEL) programme aims to reduce SABA overuse through supported implementatio... Read More about Improving asthma care through implementation of the SENTINEL programme: findings from the pilot site.
The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial (2023)
Journal Article
Friedrich, C., Francke, K., Birring, S. S., van den Berg, J. W. K., Marsden, P. A., McGarvey, L., Turner, A. M., Wielders, P., Gashaw, I., Klein, S., & Morice, A. H. (2023). The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial. Respiratory Research, 24(1), Article 109. https://doi.org/10.1186/s12931-023-02384-8BACKGROUND: P2X3 receptor antagonists seem to have a promising potential for treating patients with refractory chronic cough. In this double-blind, randomized, placebo-controlled study, we investigated the efficacy, safety, and tolerability of the no... Read More about The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial.
Modulation of transient receptor potential (TRP) channels by plant derived substances used in over-the-counter cough and cold remedies (2023)
Journal Article
Stinson, R. J., Morice, A. H., & Sadofsky, L. R. (2023). Modulation of transient receptor potential (TRP) channels by plant derived substances used in over-the-counter cough and cold remedies. Respiratory Research, 24(1), Article 45. https://doi.org/10.1186/s12931-023-02347-zBackground: Upper respiratory tract infections (URTIs) impact all age groups and have a significant economic and social burden on society, worldwide. Most URTIs are mild and self-limiting, but due to the wide range of possible causative agents, inclu... Read More about Modulation of transient receptor potential (TRP) channels by plant derived substances used in over-the-counter cough and cold remedies.
Antitussive efficacy of the current treatment protocol for refractory chronic cough: our real-world experience in a retrospective cohort study (2023)
Journal Article
Zhang, M., Morice, A. H., Si, F., Zhang, L., Chen, Q., Wang, S., Zhu, Y., Xu, X., Yu, L., & Qiu, Z. (2023). Antitussive efficacy of the current treatment protocol for refractory chronic cough: our real-world experience in a retrospective cohort study. Therapeutic Advances in Respiratory Disease, 17, https://doi.org/10.1177/17534666231167716BACKGROUND: The management of refractory chronic cough (RCC) is a great challenge. Neuromodulators have long been used for RCC with imperfect efficacy. OBJECTIVES: We summarized the outcomes of the current treatments used at our specialist cough clin... Read More about Antitussive efficacy of the current treatment protocol for refractory chronic cough: our real-world experience in a retrospective cohort study.